Cue Biopharma, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:CUE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 22.25 M40.71 M31.64 M42.21 M30.88 M Total liabilities 15.67 M22.55 M18.4 M15.78 M9.27 M Total equity 6.58 M18.16 M13.25 M26.43 M21.61 M Total liabilities & shareholders' equities 22.25 M40.71 M31.64 M42.21 M30.88 M Total debt —2.71 M1.75 M—— Net debt —-24.79 M-16.92 M——

News

Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE)

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.31%

Morning News Wrap-Up, 5/1/26: Today’s Biggest Stock Market Stories! - TipRanks.com

What's Behind The Drop In Cue Biopharma Stock Today? - Cue Biopharma (NASDAQ:CUE)

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases - Slideshow (NASDAQ:CUE) 2026-04-09

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma earnings beat by $0.10, revenue topped estimates

Cue Biopharma prices $10 million public offering at $0.28 per share

Cue Biopharma stock tumbles on public offering announcement

Cue Biopharma launches public offering of common stock and warrants

Cue Biopharma stock rating reiterated at Market Outperform by Citizens

ImmunoScape licenses Cue Biopharma technology for novel cancer therapy